Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells
Metabolic Syndrome and Related Disorders · 2023
DOI: 10.1089/met.2022.0069 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolic Syndrome and Related Disorders, 2023. Verfasst von Seshagiri Rao Nandula und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Veterans Affairs Medical Center, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Insulin Resistance, Adult Stem Cells. Die Arbeit nennt 85 Literaturangaben.
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder that is associated with abnormal accumulation of fat in the liver, which can lead to a wide variety of pathological liver defects and associated insulin resistance (IR), obesity, hypertension, dyslipidemia, diabetes, and cardiovascular disease. The molecular mechanisms that cause the initiation and progression of NAFLD are not fully understood. Increased lipolysis and de novo hepatic lipid synthesis lead to oxidative stress induced by reactive oxygen species and inflammation. Both these two entities could be interrelated and be an important mechanistic pathway, which can lead to tissue injury and hepatic cell death. Mechanisms for worsening of NAFLD include mitochondrial abnormalities, downregulation of glutathione (GSH), decreased activity of GSH-dependent antioxidants, accumulation of activated macrophages, hepatic inflammation, systemic inflammation, IR, and poorly controlled type 2 diabetes mellitus. Although no specific therapy has been approved for NAFLD, we review the latest medical therapeutics with emphasis on stem cell-based possibilities based on the presumed pathophysiology of NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Medicine, Veterans Affairs Medical Center, Washington, District of Columbia, USA.
- Department of Biochemistry and Molecular Medicine, The George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia, USA.
ORCID-Profile: Sabyasachi Sen
Zitieren
APA
Nandula, S. R., Nylen, E. S., & Sen, S. (2023). Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells. Metabolic Syndrome and Related Disorders. https://doi.org/10.1089/met.2022.0069
Vancouver
Nandula SR, Nylen ES, Sen S. Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells. Metabolic Syndrome and Related Disorders. 2023. doi:10.1089/met.2022.0069
BibTeX
@article{Nandula2023,
author = {Nandula, Seshagiri Rao and Nylen, Eric S and Sen, Sabyasachi},
title = {Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells},
journal = {Metabolic Syndrome and Related Disorders},
year = {2023},
doi = {10.1089/met.2022.0069}
}
EUVIMED